Key Segmentation
By Test Type
-
Hemoglobin Electrophoresis
-
High-Performance Liquid Chromatography
-
Point-of-Care Tests
-
Others
By Age Group
-
Newborn Screening
-
Adult Screening
-
Other Age Groups
By Sector Type
-
Government Labs
-
Private Labs
-
Corporate Labs
-
Public-Private Partnerships
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: North America dominated with 43.60% of global revenues in 2025, led by the United States with all-50-states newborn screening mandates, approximately 100,000 affected Americans requiring ongoing diagnostic monitoring, significant NIH research investment, and the most advanced gene therapy clinical infrastructure creating diagnostic demand for patient evaluation and post-treatment monitoring.
Ans: Point-of-Care Tests are the fastest-growing test type, driven by critical public health necessity of making accurate sickle cell diagnosis accessible in community clinic environments of sub-Saharan Africa and rural India where laboratory-based testing infrastructure is unavailable.
Ans: Hemoglobin Electrophoresis dominated the market in 2025 as the established diagnostic method for sickle cell disease confirmation and haemoglobin variant identification.
Ans: Progressive expansion of government-mandated newborn sickle cell screening programmes globally creating institutional testing demand, combined with the gene therapy era requirement for comprehensive pre-treatment patient evaluation and post-treatment monitoring diagnostic testing.
Ans: The Sickle Cell Anemia Testing and Screening Market was valued at USD 494.8 million in 2025.
Ans: The Sickle Cell Anemia Testing and Screening Market is expected to grow at a CAGR of 12.30% from 2026 to 2035.
Get in Touch
